Abstract
Calcific uremic arteriolopathy (CUA) is a small vessel vasculopathy affecting mainly stage IV and V renal failure patients. It is characterized typically by non-healing, painful skin ulcerations and carries a poor prognosis. Little is known about the pathogenesis, but abnormal mechanisms of vascular calcification have been postulated to contribute. Available therapies target promotion of wound healing and lowering of elevated parathyroid hormone levels and the calcium-phosphate product. There are no prospective or randomized controlled trials to guide choice of therapeutic agents, yet available therapies may subject patients to adverse side effects, and/or increase program expenditures. Therefore, we favor a graded approach to treatment of CUA, commencing conservatively with the least harmful and most cost-efficient measures available.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
